A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

被引：2

作者：

Mazza, Irit Avivi ^{[1
,2
]}

Barba, Pere ^{[3
]}

Yuda, Junichiro ^{[4
]}

Palomba, Maria Lia ^{[5
]}

Alderuccio, Juan Pablo ^{[6
]}

de Vriendt, Ciel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Jain, Nitin ^{[12
]}

Leonard, Jessica T. ^{[13
]}

Coulson, Michelle ^{[14
]}

Hassounah, Nadia ^{[14
]}

Yang, Xiaoling ^{[14
]}

Lu, Haihui ^{[14
]}

Lewandowski, Andrew ^{[14
]}

Polli, Joseph Ryan ^{[14
]}

Klopfenstein, Matthieu

Pastore, Alessandro ^{[15
]}

Brisou, Gabriel ^{[16
]}

机构：

[1] Tel Aviv Univ, BMT Unit, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[3] Vall DHebron Inst Oncol VHIO, Hosp Univ Vall DHebron, Deparment Hematol, La Garriga, Spain

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Mem Sloan Kettering Canc Ctr, Cellular Therapy Serv, New York, NY USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[7] Univ Hosp Ghent Univ Ziekenhuis, Ghent, Belgium

[8] Univ Milan, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[13] Oregon Hlth & Sci Univ, Dept Med Hematol Oncol, Portland, OR USA

[14] Novartis Inst BioMed Res, Cambridge, MA USA

[15] Novartis Inst BioMed Res, Basel, Switzerland

[16] Inst Paoli Calmettes, Dept Hematol, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[31] A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Budde, Elizabeth
Gopal, Ajay K.
Kim, Won Seog
Flinn, Ian W.
Cheah, Chan Yoon Y.
Nastoupil, Loretta
Matasar, Matthew J.
Diefenbach, Catherine S.
Gregory, Gareth P.
Qazi, Ibrahim
Pang, Ching-Fai
Leabman, Maya
Hernandez, Genevive
Sison, Iris
Keyt, Bruce A.
Chen, Daniel
Armand, Philippe
BLOOD, 2021, 138
[32] MONOCLONAL ANTI-CD44 ANTIBODY ACTS IN SYNERGY WITH ANTI-CD2 BUT INHIBITS ANTI-CD3 OR T-CELL RECEPTOR-MEDIATED SIGNALING IN MURINE T-CELL HYBRIDOMAS
GUO, YJ
MA, J
WONG, JH
LIN, SC
CHANG, HC
BIGBY, M
SY, MS
CELLULAR IMMUNOLOGY, 1993, 152 (01) : 186 - 199
[33] Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review
Becerril-Rico, Jared
Delgado-Montes, Yerenia A. A.
Ortiz-Sanchez, Elizabeth
LEUKEMIA & LYMPHOMA, 2023, 64 (11) : 1822 - 1831
[34] Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy
Colton, Meryl
Purev, Enkhtsetseg
Haverkos, Bradley
Bair, Steven
Jasem, Jagar
Jacob, Allison
Kamdar, Manali
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (11): : 778 - 782
[35] Immunotherapy with FBTA05 (Bi20), a trifunctional anti-CD3 x anti-CD20 antibody in recurrent childhood B-cell malignancies
Schuster, F.
Stanglmaier, M.
Woessmann, W.
Winkler, B.
Meisel, R.
Schlegel, P. G.
Lindhofer, H.
Reiter, A.
Borkhardt, A.
Buhmann, R.
BONE MARROW TRANSPLANTATION, 2011, 46 : S247 - S247
[36] REGULATION BY ANTI-CD2 MONOCLONAL-ANTIBODY OF THE ACTIVATION OF A HUMAN T-CELL CLONE INDUCED BY ANTI-CD3 OR ANTI-T CELL-RECEPTOR ANTIBODIES
YSSEL, H
AUBRY, JP
MALEFIJT, RD
DEVRIES, JE
SPITS, H
JOURNAL OF IMMUNOLOGY, 1987, 139 (09): : 2850 - 2855
[37] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Hui Zhou
Yuling Luo
Sha Zhu
Xi Wang
Yunuo Zhao
Xuejin Ou
Tao Zhang
Xuelei Ma
BMC Cancer, 18
[38] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Earl, Christian Tyler
Wilding, Emily
Quinion, Carl
Lustberg, Mark
Benson, Don M., Jr.
Jones, Jeffrey A.
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2010, 116 (21) : 1148 - 1149
[39] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis
Zhou, Hui
Luo, Yuling
Zhu, Sha
Wang, Xi
Zhao, Yunuo
Ou, Xuejin
Zhang, Tao
Ma, Xuelei
BMC CANCER, 2018, 18
[40] INHIBITION BY ANTI-CD2 MONOCLONAL-ANTIBODIES OF ANTI-CD3-INDUCED T-CELL-DEPENDENT B-CELL ACTIVATION
STOHL, W
CROW, MK
CELLULAR IMMUNOLOGY, 1990, 130 (02) : 257 - 270

← 1 2 3 4 5 →